Identification | Back Directory | [Name]
3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione | [CAS]
198474-05-4 | [Synonyms]
EOS200271 PF-06840003 PF-06840003 (racemate) PF 06840003;PF-06840003 3-(5-fluoro-indol-3-yl)-pyrrolidine-2,5-dione 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione 3-(5-Fluoro-1H-indol-3-yl)-2,5-pyrrolidinedione 2,5-Pyrrolidinedione, 3-(5-fluoro-1H-indol-3-yl)- | [Molecular Formula]
C12H9FN2O2 | [MDL Number]
MFCD25121820 | [MOL File]
198474-05-4.mol | [Molecular Weight]
232.21 |
Chemical Properties | Back Directory | [Melting point ]
190-195 °C | [Boiling point ]
533.2±50.0 °C(Predicted) | [density ]
1.464±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Soluble in DMSO (up to at least 25 mg/ml) | [form ]
solid | [pka]
9.13±0.50(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Hazard Information | Back Directory | [Description]
PF-06840003 (198474-05-4) is a potent (IC50?= 150 and 410 nM via two methods) and selective inhibitor of Indoleamine-2,3-dioxygenase (IDO1).1?In mice with syngeneic tumor grafts, it reduced intratumoral kynurenine levels by over 80%, inhibited tumor growth as monotherapy, and increased the efficacy of anti-PD-L1 therapy.2?PF-06840003 treatment combined with GM-CSF-secreting allogenic pancreatic tumor cell vaccine (GVAX) resulted in increased antitumor efficacy in a murine model of pancreatic ductal adenocarcinoma.3 | [Uses]
PF-06840003 is a potential clinical candidate as a novel and selective Indoleamine 2,3-dioxygenase inhibitor. Highly selective and orally bioavailable IDO-1 inhibitor. | [Synthesis]
The general procedure for the synthesis of 3-(5-fluoro-1H-indol-3-yl)-2,5-pyrrolidinedione from maleimide and 5-fluoroindole was as follows: 5-fluoroindole (5.00 g, 35.5 mmol, 96 wt%) was mixed with maleimide (5.17 g, 53.3 mmol, 1.5 eq.) in a 50 mL reaction vessel followed by addition of acetonitrile ( 15.0 mL, 11.7 g, 286 mmol, 100 wt%) and zinc chloride (5.08 g, 37.3 mmol, 1.05 equiv). The reaction mixture was heated to 85 °C within 10 min and maintained at this temperature for 24 h. The reaction was carried out at a temperature of 0.5 °C. The reaction was carried out at a temperature of 0.5 °C. During the reaction, the temperature was maintained above 80 °C and water (30.0 mL, 30.0 g, 1670 mmol, 100 wt%) was slowly added and yellow solid precipitation was observed. Subsequently, the reaction mixture was cooled to 50 °C over 1 h and stirred at this temperature for 2 h, after which it continued to be cooled to 10 °C over 1 h and stirred at 10 °C for 1 h. The reaction mixture was then cooled to 50 °C over 1 h and stirred at 10 °C for 2 h. The reaction mixture was then The solid was collected by filtration and the filter cake was washed twice with 5 mL of a 1:1 acetonitrile/water mixture to give the crude product (6.85 g, 29.5 mmol, 83.1% yield). To purify the crude product, it (6.85 g, 29.5 mmol, 100 wt%) was dissolved in tetrahydrofuran (41.1 mL, 36.4 g, 505 mmol, 100 wt%) and heated to 66 °C to form a homogeneous solution. Heptane (27.4 mL, 18.7 g, 187 mmol, 100 wt%) was slowly added at 66 °C and the solid was observed to start precipitating. The mixture was cooled to 25 °C over 3 h, filtered and washed with heptane, followed by drying in a high vacuum oven overnight to give the purified product (4.93 g, 21.2 mmol, 100 wt%, 72.0% yield). For further purification, the above product (1.00 g, 4.3 mmol, 100 wt%) was mixed with tetrahydrofuran (6 mL, 100 wt%) and heptane (6 mL, 100 wt%) in a 50 mL vessel and stirred for 48 h at 25 °C. The product was purified by washing with a solvent and dried in a high vacuum oven overnight. The solid was collected by filtration and dried in a high vacuum oven overnight to give the final product (0.89 g, 3.83 mmol, 100 wt%, 89.00% yield). | [in vivo]
PF-06840003 reduces intratumoral kynurenine levels in mice by >80% and inhibits tumor growth in multiple preclinical syngeneic models in mice, in combination with immune checkpoint inhibitors. PF-0684003 has favorable predicted human pharmacokinetic properties, including a predicted t1/2 of 16-19 hours[1]. | [IC 50]
IDO-1 | [storage]
Store at -20°C | [References]
1) Crosignani?et al.?(2017),?Discovery of a Novel and Selective Indoleamine-2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EROS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate;?J. Med. Chem.?60?9617
2) Gomes?et al.?(2018),?Characterization of the Selective Indoleamine-2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy;?Mol. Cancer Ther.?9?2530
3) Blair?et al.?(2019),?IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma;?J. Clin. Invest.?129?1742 |
|
|